Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Blanquart

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Oncotarget|April 30, 2016
Characterization of preneoplastic and neoplastic rat mesothelial cell lines: the involvement of TETs, DNMTs, and 5-hydroxymethylcytosineDavid Roulois, Sophie Deshayes, Marie-Noëlle Guilly, et al.
Frontiers in Immunology|August 4, 2023
ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progressionMargot Lavy, Vanessa Gauttier, Alison Dumont, et al.
Cancer Immunology, Immunotherapy : CII|July 19, 2023
Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cellsMarion Grard, Mohamed Idjellidaine, Atousa Arbabian, et al.
Scientific Reports|March 2, 2021
A partially demineralized allogeneic bone graft: in vitro osteogenic potential and preclinical evaluation in two different intramembranous bone healing modelsPierre Tournier, Jérôme Guicheux, Arnaud Paré, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2023
Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesotheliomaPaul Stockhammer, Hannah Baumeister, Till Ploenes, et al.
Molecular Therapy. Oncology|January 1, 2026
Development of potent Affitin-based bispecific NK cell engagers for the therapy of MSLN-expressing cancersTina Briolay, Tacien Petithomme, Hermelyne Gravoueille, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesotheliomaThibaut Blondy, Sènan Mickael d'Almeida, Tina Briolay, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 28, 2025
In vitro models to mimic tumor endothelial cell-mediated immune cell reprogramming in lung adenocarcinomaMorgane Krejbich, Emilie Navarro, Judith Fresquet, et al.
Oncoimmunology|July 15, 2024
Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironmentCamille Chatelain, Laurine Berland, Marion Grard, et al.
Ebiomedicine|October 29, 2024
The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivityMégane Willems, Malik Hamaidia, Alexis Fontaine, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Oncotarget|April 30, 2016
Characterization of preneoplastic and neoplastic rat mesothelial cell lines: the involvement of TETs, DNMTs, and 5-hydroxymethylcytosineDavid Roulois, Sophie Deshayes, Marie-Noëlle Guilly, et al.
Frontiers in Immunology|August 4, 2023
ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progressionMargot Lavy, Vanessa Gauttier, Alison Dumont, et al.
Cancer Immunology, Immunotherapy : CII|July 19, 2023
Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cellsMarion Grard, Mohamed Idjellidaine, Atousa Arbabian, et al.
Scientific Reports|March 2, 2021
A partially demineralized allogeneic bone graft: in vitro osteogenic potential and preclinical evaluation in two different intramembranous bone healing modelsPierre Tournier, Jérôme Guicheux, Arnaud Paré, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2023
Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesotheliomaPaul Stockhammer, Hannah Baumeister, Till Ploenes, et al.
Molecular Therapy. Oncology|January 1, 2026
Development of potent Affitin-based bispecific NK cell engagers for the therapy of MSLN-expressing cancersTina Briolay, Tacien Petithomme, Hermelyne Gravoueille, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesotheliomaThibaut Blondy, Sènan Mickael d'Almeida, Tina Briolay, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 28, 2025
In vitro models to mimic tumor endothelial cell-mediated immune cell reprogramming in lung adenocarcinomaMorgane Krejbich, Emilie Navarro, Judith Fresquet, et al.
Oncoimmunology|July 15, 2024
Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironmentCamille Chatelain, Laurine Berland, Marion Grard, et al.
Ebiomedicine|October 29, 2024
The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivityMégane Willems, Malik Hamaidia, Alexis Fontaine, et al.
Pageof 8